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RChoice of Appropriate Endpoints
for a Balloon Versus Stent Trial
The recent paper by Latib et al. (1) compared the efficacy of a
paclitaxel-eluting balloon (PEB) with that of a paclitaxel-eluting
stent (PES) at preventing restenosis after percutaneous coronary
intervention in coronary arteries 2.8 mm in diameter. The
prespecified primary endpoint was in-stent, or in-balloon, angio-
graphic late lumen loss (LLL). Although the sample size was based
on a noninferiority hypothesis, the authors found that the PEB was
superior to the PES “in suppressing neointimal proliferation.” The
implication of this finding was that the PEB may be a better
revascularization option than PES.
LLL is an appropriate surrogate endpoint for the comparison of
antirestenotic efficacy of different drug-eluting stents in which the
increase in lumen diameter achieved in the index procedure is
similar. Unfortunately, the current study compares “apples with
oranges.” LLL is not an appropriate endpoint for a comparison of
a balloon and a stent procedure because, although LLL is greater
with a stenting procedure, the acute gain with stenting is greater
(1.37  0.31 mm vs. 0.96  0.30 mm; p  0.001). This finding
more than offsets the LLL so that luminal diameter at follow-up
is significantly larger with stenting (1–3). In the current study, the
minimal lumen diameter at 6 months for PES (1.68  0.51 mm)
was superior to PEB (1.48  0.41 mm) (p  0.006). Luminal
diameter (or radius), but not LLL, is a major parameter defined by
Poiseuille’s equation contributing directly to lesion hemodynamic
significance. These data do not support the contention that PEB
are superior to PES in the treatment of small coronary vessel
disease.
Furthermore, when comparing balloon- and stent-based treat-
ments, differences in LLL do not indicate differences in suppres-
sion of intimal hyperplasia. The mechanisms of restenosis differ
between groups. Although in-stent restenosis is a process of
smooth muscle cell migration and proliferation (4), restenosis after
balloon angioplasty is a more complex combination of early vessel
recoil and later negative remodeling, and to a lesser extent cell
proliferation (5). For these reasons, differences in LLL cannot be
attributed, as the authors do, to differences in efficacy in suppress-
ing intimal hyperplasia.
Although this study provides insights into the relative efficacy of
balloons and stents coated with paclitaxel, larger studies with
newer antiproliferative drugs in the stent arm, and more appropri-
ate angiographic endpoints, are still needed.
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Paclitaxel-Eluting Balloons
for Small-Vessel Disease
We read with great interest the study by Latib et al. (1) suggesting
that treatment of small-vessel disease (SVD) with paclitaxel-
eluting balloons was associated with less angiographic late loss and
rates of revascularization similar to paclitaxel-eluting stents (PES).
The study is of major clinical interest because there is scarce
information on the value of paclitaxel-eluting balloons in complex
de novo lesions, as those in SVD (2). However, late lumen loss
may be misleading as a primary endpoint when these inherently
different technologies are compared. Indeed, as illustrated by the
classical dictum “the more you gain, the more you lose” (3), balloon
therapy is systematically associated with a lower late loss, as a result
of its lower acute gain, compared with stents (4). Late loss is also
significantly related to vessel size, which, in this study, was
significantly smaller in the drug-eluting balloon (DEB) arm.
Therefore, in this situation, most investigators would favor the use
of other angiographic endpoints (namely, percent diameter steno-
sis or even minimal lumen diameter) at follow-up as surrogate
markers of efficacy because they are relatively independent from the
acute gain. Moreover, these late angiographic findings are more
closely associated with clinical endpoints (as target lesion revascu-
larization) than the mechanistically oriented late loss angiographic
parameter. The problem is that in the study by Latib et al. (1), both
minimal lumen diameter (1.68  0.51 mm vs. 1.48  0.41 mm;
